Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 196

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 196
---
 on our website any materials
required to be so posted on such website under applicable corporate or securities laws and regulations, including, posting any XBRL interactive
financial data required to be filed with the SEC and any notices of general meetings of our shareholders.

<div align='center'>116

Up to 4,975,124 Class A Ordinary Shares

Warrants to Purchase up to 2,487,562 Class A Ordinary Shares

Up to 2,487,562 Class A Ordinary Shares Issuable Upon Exercise of Warrants

NewGenIvf Group Limited

PROSPECTUS

, 2025

NEWGENIVF LIMITED</div>

| AUDITED                                                                                                       
 CONSOLIDATED FINANCIAL STATEMENTS                                                                             |     |     |
| Report of Independent Registered Public Accounting                                                            
 Firm (PCAOB ID: 1171)                                                                                         |     | F-2 |
| Report                                                                                                        
 of Independent Registered Public Accounting Firm (PCAOB ID: 6743)                                             |     | F-4 |
| Consolidated                                                                                                  
 Balance Sheets as of December 31, 2024 and 2023                                                               |     | F-5 |
| Consolidated                                                                                                  
 Statements of Operations and Comprehensive Income (Loss) for the Years Ended December 31, 2024, 2023 and 2022 |     | F-6 |
| Consolidated                                                                                                  
 Statements of Changes in Shareholders’ Equity (Deficit) for the Years Ended December 31, 2024, 2023 and 2022  |     | F-7 |
| Consolidated                                                                                                  
 Statements of Cash Flows for the Years Ended December 31, 2024, 2023 and 2022                                 |     | F-8 |
| Notes                                                                                                         
 to the Consolidated Financial Statements                                                                      |     | F-9 |

<div align='center'>F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

| To: | The Board of Directors                
 and Shareholders of NewGenIvf Limited |

Opinion on the Financial Statements

We have audited the accompanying
consolidated balance sheets of NewGenIvf Limited and its subsidiaries (collectively the “Company”) as of December 31,
2021 and 2022, and the related consolidated statements of operations and comprehensive income (loss), changes in shareholders’
equity (deficit), and cash flows in each of the years for the two-year period ended December